Anika Therapeutics vs AVITA Medical
ANIK and RCEL side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ANIK and RCEL compare
AVITA Medical is the larger company, worth 2.7 times as much as Anika Therapeutics ($483M against $179M).
AVITA Medical grew revenue faster over the last twelve months (17.0% versus 9.4% for Anika Therapeutics).
Anika Therapeutics keeps more of each dollar of sales as profit, with a net margin of −1.4% compared with −42.7% at AVITA Medical.
Anika Therapeutics scores higher on the StockData Score (11 against 5 for AVITA Medical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ANIK | RCEL |
|---|---|---|
| Size and price | ||
| Market cap | $179M | $483M |
| Share price | $13.40 | $15.63 |
| Change, 1 year | 32.7% | 313% |
| Change, 5 years | −66.6% | 4.3% |
| Beta (5Y) | 0.86 | 1.97 |
| Employees | 235 | 226 |
| StockData Score | ||
| Total score | 11 (better) | 5 |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 | 3 (better) |
| Performance score | 3 (better) | 1 |
| Health score | 6 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.5× (better) | 5.7× |
| P/B | 1.3× | – |
| EV/EBITDA | 43.8× | – |
| P/FCF | 78.1× | – |
| FCF yield | 1.3% (better) | −4.0% |
| Fair value | $12.84 | – |
| Margin of safety | −4.4% | – |
| Growth | ||
| Revenue growth (TTM) | 9.4% | 17.0% (better) |
| Revenue growth, 5Y average | −2.9% | 67.2% (better) |
| Profitability | ||
| Gross margin | 63.4% | 82.4% (better) |
| Operating margin | −2.1% (better) | −33.9% |
| Net margin | −1.4% (better) | −42.7% |
| FCF margin | 1.9% (better) | −22.8% |
| Return on equity | −1.2% | – |
| Return on invested capital | −2.6% (better) | −276% |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −5.1× |
| Current ratio | 3.86 (better) | 1.20 |
| Altman Z-score | 3.59 (better) | −9.32 |
| Piotroski F-score | 6 (better) | 3 |
| Dividends and buybacks | ||
| Buyback yield | 8.4% | – |
| Shareholder yield | 8.4% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 91.9% | 15.9% |
| Held by insiders | 16.9% | 2.7% |
| Insider net buying, 12 months | $264K (better) | $235K |
| Short interest, % of float | 2.9% | – |
Go deeper
- ANIK stock overview
- ANIK income statement
- ANIK valuation and score
- RCEL stock overview
- RCEL income statement
- RCEL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.